Should FDA Make Patients Care About A Problem If They Don’t Already?
Executive Summary
FDA’s Risk Communication Advisory Committee discusses best ways to communicate uncertainty, including how aggressive FDA should be with groups that are not engaged in its messages.
You may also be interested in...
Risk Communication Panel To Continue Discussion Of Uncertainty Messaging
FDA looking for more help from advisory committee on how much information about uncertainty to give as well as how best to communicate it to minority, uneducated groups.
Can't Please Everybody: FDA's "Brief Summary" Redesign May Require Flexibility
Drug Facts Box format scored well in a broad study, but researchers found it may not be the best format for everyone.
Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director
Nicole Verdun said children could participate in gene therapy clinical trials earlier if the necessary controls are in place.